MML Investors Services LLC Purchases New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

MML Investors Services LLC purchased a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 14,497 shares of the specialty pharmaceutical company's stock, valued at approximately $1,785,000.

Several other institutional investors have also recently made changes to their positions in JAZZ. LSV Asset Management boosted its holdings in Jazz Pharmaceuticals by 1.5% in the 4th quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock worth $311,699,000 after buying an additional 37,108 shares during the period. Pacer Advisors Inc. grew its holdings in Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after buying an additional 115,102 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 18.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after buying an additional 320,724 shares in the last quarter. Capital World Investors lifted its stake in shares of Jazz Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock valued at $236,860,000 after purchasing an additional 104,195 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Jazz Pharmaceuticals by 4.8% in the fourth quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock worth $195,506,000 after buying an additional 72,007 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Analyst Upgrades and Downgrades

JAZZ has been the subject of several recent analyst reports. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their target price for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and upped their target price for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Morgan Stanley reiterated an "overweight" rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. JPMorgan Chase & Co. lifted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, Royal Bank of Canada cut their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $187.71.

Insider Activity

In other news, CMO Robert Iannone sold 7,080 shares of the company's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares in the company, valued at $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Patricia Carr sold 1,140 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares of the company's stock, valued at approximately $966,323.72. This represents a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,023,305 over the last ninety days. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded up $2.87 during midday trading on Friday, hitting $120.05. The company had a trading volume of 1,200,496 shares, compared to its average volume of 804,364. The stock has a market cap of $7.40 billion, a price-to-earnings ratio of 16.91, a PEG ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a fifty day simple moving average of $122.63 and a 200 day simple moving average of $122.42.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.